Bosch and Randox Laboratories Ltd. announced a strategic partnership on Wednesday, April 10, 2024. The two companies are set to invest around 150 million euros in joint research, development, and sales activities for new tests for the Vivalytic analysis platform provided by Bosch Healthcare.
One of the main goals of this partnership is the development of a sepsis IVD grade (in-vitro diagnostics) test, which will be the first to feature highly innovative and novel BioMEMS technology. This new technology will be implemented in the Vivalytic test cartridges and will allow for the testing of more than 250 genetic characteristics in less than 15 minutes.
Bosch is looking to expand in the field of molecular diagnostics and is contributing its technology and manufacturing expertise in molecular diagnostics, microchip development and manufacturing, and miniaturization. “Globally, healthcare is moving towards decentralized and personalized diagnostics, that enable rapid interventions and individual treatment plans,” says Marc Meier, managing director of Bosch Healthcare Solutions GmbH. “With our partner Randox, we want to further expand the test portfolio of our Vivalytic analysis device. Our fully automated molecular-diagnostic PCR tests provide clarity directly at the site of sample collection, shorten waiting times, and take the strain off the healthcare system,” Meier adds.
The development partnership with Randox will focus on the implementation of a highly sensitive multiplex test for sepsis on the Vivalytic analysis platform. Dr. Peter Fitzgerald, Managing Director of Randox Laboratories Ltd., explains the importance of this test: “Clinical outcomes in sepsis depend on timely diagnosis and appropriate early therapeutic intervention. Current methods of sepsis diagnosis are insufficient and time-consuming. With over 10 years of experience in the field of infectious diseases diagnostics, we aim to develop a state-of-the-art sepsis test using a highly multiplexing BioMEMS chip. Such a test could revolutionize sepsis diagnosis, ultimately leading to improved treatment outcomes and lower mortality rates from this life-threatening condition.”
The BioMEMS chip, which combines microelectromechanical systems (MEMS) with microfluidics, will allow for the testing of multiple genetic characteristics in a single cartridge in a matter of minutes. This technology has the potential to be used in the field of oncology in the future. “Our test cartridge is a highly complex laboratory the size of a smartphone, so to speak,” says Meier.
For press inquiries, please contact Thomas Berroth at Thomas.berroth2@de.bosch.com or +49 (0) 160 90437856.
Distributed by https://pressat.co.uk/
